The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2020 | Using MRD to guide treatment decisions in the clinic
Jesus San Miguel, MD, Universidad de Navarra, Navarra, Spain, discusses the use of measurable residual disease (MRD) to guide treatment decisions outside clinical trials. In other forms of cancer, such as prostate and breast cancer, residual disease is combated. Therefore, we should have the same approach in myeloma. In clinical trials, MRD has indicated a clear endpoint that correlates with overall survival. MRD can also be used to compare the response of multiple treatment regimens. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
Disclosures
Consulting or Advisory role for Amgen, BMS, Celgene, Janssen, MSD, Novartis, Takeda, Sanofi, Roche, GSK, Abbvie and Karyopharm.
